Clinical experiences with human parathyroid hormone 1-34.
Human parathyroid hormone (PTH) 1-34 was given to nine normal subjects and to 10 patients with hypoparathyroidism. There were no side effects associated with the protocol employed. In normal subjects, five statistically significant changes occurred during the period of observation: plasma cyclic adenosine monophosphate (cAMP) rose by a factor of 3 (at 30 min), nephrogenous cyclic AMP rose approximately 40-fold (at 60 min), urinary phosphate rose by a factor of 2 (at 120 min), urine calcium levels fell by 50% between 60 and 120 min, and plasma prolactin rose by a factor of 1.4 (at 60 min). The cAMP responses were significantly blunted in five patients with chronic hypocalcemia, chronic hyperphosphatemia, and detectable serum immunoreactive PTH levels. On the basis of this test these patients were designated as suffering from pseudohypoparathyroidism. The acute phosphaturic and hypocalciuric responses were apparently intact in these five individuals. Human PTH 1-34 is likely to replace bovine material in the delineation of syndromes associated with PTH resistance.
D000328:Adult; D002118:Calcium / Q000652:urine; D002986:Clinical Trials as Topic; D000242:Cyclic AMP / Q000097:blood; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007011:Hypoparathyroidism / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000627:therapeutic use*; D010710:Phosphates / Q000652:urine; D011388:Prolactin / Q000097:blood; D011547:Pseudohypoparathyroidism / Q000175:diagnosis; D019379:Teriparatide
D010281:Parathyroid Hormone; D010446:Peptide Fragments; D010710:Phosphates; D019379:Teriparatide; D011388:Prolactin; D000242:Cyclic AMP; D002118:Calcium